durvalumab,sorafenib,tremelimumab
astrazeneca,pfizer
['himalaya', 'hcc']
os and #imaes in patients with advanced #hcc treated with #stride in the himalaya phase 3 trial #asco23 
Associate Professor of Medical Oncology at HUNIMED, GI cancer specialist with research interest in #livercancer, #HCC, #biliarytractcancer, #cholangiocarcinoma